Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways

World Journal of Hepatology

Volumn 7, Issue 22, 2015, Pages 2384-2388

  Perumpail, Ryan B ^a   Ahmed, Aijaz ^a   Liu, Andy ^b   Wong, Robert J ^c   Harrison, Stephen A ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Alameda Health System   (United States)

^d SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

Hepatocellular carcinoma; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

EID: 84943392063     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i22.2384     Document Type: Short Survey

References (36)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303: 235-241 [PMID:20071471 DOI:10.1001/jama.2009.2014]
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy:a prospective study. Gastroenterology 2011;140:124-131 [PMID:20858492 DOI:10.1053/j.gastro.2010.09.038]
3. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-858 [PMID:22446927 DOI:10.1016/j.cgh.2012.03.011]
4. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis:clinical characterization and risk factors for underlying disease. Hepatology 1999;29: 664-669 [PMID:10051466 DOI:10.1002/hep.510290347]
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection. Hepatology 2010;51:1820-1832 [PMID:20432259 DOI:10.1002/hep.23594]
6. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease:an emerging menace. J Hepatol 2012;56:1384-1391 [PMID:22326465 DOI:10.1016/j.jhep.2011.10.027]
7. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma:our case series and literature review. World J Gastroenterol 2010;16:1436-1441 [PMID:20333782 DOI:10.3748/wjg.v16.i12.1436]
8. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis:a pathological analysis. Hepatology 2009;49:851-859 [PMID:19115377 DOI:10.1002/hep.22734]
9. Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 2009;42:958-962 [PMID:19787150 DOI:10.1590/S0100-879X2009005000019]
10. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T;Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-433;quiz e50 [PMID:21320639]
11. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-1766 [PMID:18976012]
12. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638 [PMID:12711737 DOI:10.1056/NEJMoa021423]
13. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867 [PMID:17167474 DOI:10.1038/nature05485]
14. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma:mechanisms and implications. Gut 2010;59:1303-1307 [PMID:20650925 DOI:10.1136/gut.2009.199661]
15. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 2006;5: 259-269 [PMID:17178701 DOI:10.14310/horm.2002.11190]
16. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208 [PMID:20141834 DOI:10.1016/j.cell.2009.12.052]
17. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506 [PMID:22136659 DOI:10.1186/1471-2407-11-506]
18. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011;17: 3922-3932 [PMID:22025881 DOI:10.3748/wjg.v17.i34.3922]
19. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-121 [PMID:15591515 DOI:10.1136/gut.2003.037010]
20. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101: 2476-2481 [PMID:14983034 DOI:10.1073/pnas.0308671100]
21. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009;18:2975-2988 [PMID:19454484 DOI:10.1093/hmg/ddp236]
22. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA 2007;104:14771-14776 [PMID:17785413 DOI:10.1073/pnas.0706578104]
23. Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 2006;44:1003-1011 [PMID:17006931 DOI:10.1002/hep.21293]
24. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997;40 Suppl 2:S25-S31 [PMID:9248698 DOI:10.1007/s001250051393]
25. Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma:evidence of an altered circadian rhythm. Am J Gastroenterol 1993;88:1744-1748 [PMID:8213718]
26. Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, Briscoe CP. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase. Am J Physiol Endocrinol Metab 2008;295:E1142-E1151 [PMID:18728225 DOI:10.1152/ajpendo.90298.2008]
27. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336 [PMID:12447443 DOI:10.1038/nature01137]
28. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009;49:87-96 [PMID:19053047 DOI:10.1002/hep.22578]
29. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 2009;50:323-333 [PMID:19041150 DOI:10.1016/j.jhep.2008.07.037]
30. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-758 [PMID:20331505 DOI:10.1111/j.1478-3231.2010.02223.x]
31. Hardie DG. AMP-activated/SNF1 protein kinases:conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8: 774-785 [PMID:17712357 DOI:10.1038/nrm2249]
32. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589-3594 [PMID:19812304 DOI:10.1242/jcs.051011]
33. Lee JW, Park S, Takahashi Y, Wang HG. The association of AMPK with ULK1 regulates autophagy. PLoS One 2010;5: e15394 [PMID:21072212 DOI:10.1371/journal.pone.0015394]
34. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma:fertile soil. Semin Liver Dis 2012;32:30-38 [PMID:22418886 DOI:10.1055/s-0032-1306424]
35. Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer development and therapy. Cancer Res 2010;70:3431-3434 [PMID:20424122 DOI:10.1158/0008-5472.CAN-09-4027]
36. Chan EY. mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex. Sci Signal 2009;2:pe51 [PMID:19690328 DOI:10.1126/scisignal.284pe51]